Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomics of GLP1 Receptor Agonists in the Amish
NCT05762744Phase 1Terminated
- Sponsor
- University of Maryland, Baltimore
- Start
- Jun 2016
- Primary completion
- Nov 2018
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by University of Maryland, Baltimore. Primary endpoints: Exenatide Effect on First Phase Insulin Secretion and Exenatide Effect on Glucose Disappearance Rate. Started Jun 2016; status: terminated.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05762744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05762744.